RAPP Rapport Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Risk Factors

• • New clinical hold risk on RAP-219 diabetic peripheral neuropathic pain trial triggered by FDA request for protocol amendments in Q4 2024
• • Updated financial risk: net losses increased to $77.7M for nine months ended Sept 2025 from $58.3M in prior year, cash $513M funding through H2 2029

What are the latest RAPP SEC filings in 2026?

Rapport Therapeutics, Inc. (RAPP) has filed a 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on April 21, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did RAPP file its most recent 10-K annual report?

Rapport Therapeutics, Inc. (RAPP) filed its most recent 10-K annual report on March 10, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view RAPP 10-Q quarterly reports?

Rapport Therapeutics, Inc. (RAPP)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every RAPP 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has RAPP filed recently?

Rapport Therapeutics, Inc. (RAPP)'s most recent 8-K was filed on April 21, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find RAPP insider trading activity (Form 4)?

SignalX aggregates every RAPP Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does RAPP file with the SEC?

Rapport Therapeutics, Inc. (RAPP) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new RAPP filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Rapport Therapeutics, Inc. (RAPP).

What is RAPP's SEC CIK number?

Rapport Therapeutics, Inc. (RAPP)'s SEC CIK (Central Index Key) number is 2012593. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 2012593 to look up all RAPP filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find RAPP return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Rapport Therapeutics, Inc. (RAPP) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.